Aficamten, a first-in-class cardiac myosin inhibitor, offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback